R&D News | pharmaphorum

News

Metsera gets $215m for obesity trials, and other financings

If any further evidence were needed for the insatiable investor appetite for companies with obesity assets, look no further than New York start-up Metsera.

News

Amgen plays down safety concern with obesity candidate

Amgen has rebuffed claims made by an analyst suggesting that its obesity drug MariTide is associated with reductions in bone mineral density that could undermine its ability to compete in t

News

BioNTech buys Biotheus and its Keytruda rival for $950m

BioNTech is clearly impressed with what it has seen with partner Biotheus' bispecific antibody for cancer, opting to buy the company outright to get full control of the drug.

News

London "is number one European city in life sciences"

A new report says that London is the top city in Europe for the life sciences industry, and ranks third worldwide after Boston and New York in the US.

News

Rachel McMinn, Neurogene's founder and chief executive

Neurogene shares fall on Rett syndrome gene therapy data

Neurogene has reported encouraging efficacy results with its gene therapy for rare genetic disorder Rett syndrome, but investors' concerns about safety seem to be weighing on its share pric

News

Merck drug for rare tumour hits phase 3 target

Merck KGaA is shaping up to take on Daiichi Sankyo and Ono Pharma in the market for tenosynovial giant cell tumour (TGCT) therapies after its drug candidate pimicotinib cleared a phase 3 tr

Metsera gets $215m for obesity trials, and other financings

Amgen plays down safety concern with obesity candidate

BioNTech buys Biotheus and its Keytruda rival for $950m

London "is number one European city in life sciences"

Neurogene shares fall on Rett syndrome gene therapy data

Merck drug for rare tumour hits phase 3 target

Senju launches first-in-class dry eye disease drug in Japan

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks